Sera Prognostics, Inc. (SERA)
NASDAQ: SERA · Real-Time Price · USD
3.630
+0.090 (2.54%)
Mar 31, 2025, 2:21 PM EDT - Market open
Company Description
Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests and predictive analytic products and services in the United States.
The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman for the prediction of the expectant mother’s risk of delivering spontaneously.
It is also developing a pipeline of novel blood-based biomarker tests for major pregnancy-related conditions, including time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction.
The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Sera Prognostics, Inc.
Country | United States |
Founded | 2008 |
IPO Date | Jul 15, 2021 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 64 |
CEO | Evguenia Lindgardt |
Contact Details
Address: 2749 East Parleys Way, Suite 200 Salt Lake City, Utah 84109 United States | |
Phone | 801 990 0520 |
Website | sera.com |
Stock Details
Ticker Symbol | SERA |
Exchange | NASDAQ |
Stock Type | Common Stock |
Share Class | Class A Shares |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $16.00 |
CIK Code | 0001534969 |
CUSIP Number | 81749D107 |
ISIN Number | US81749D1072 |
Employer ID | 26-1911522 |
SIC Code | 8071 |
Key Executives
Name | Position |
---|---|
Evguenia Lindgardt M.B.A. | President, Chief Executive Officer and Director |
Austin Aerts | Chief Financial Officer |
Dr. John J. Boniface Ph.D. | Chief Scientific Officer |
Dr. Gregory C. Critchfield M.D., M.S. | Executive Director |
Robert G. Harrison | Chief Information Officer |
Benjamin G. Jackson J.D. | General Counsel |
Dr. Paul Kearney Ph.D. | Chief Data Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 19, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 19, 2025 | 10-K | Annual Report |
Mar 19, 2025 | 8-K | Current Report |
Mar 10, 2025 | 144 | Filing |
Mar 10, 2025 | 144 | Filing |
Mar 7, 2025 | 144 | Filing |
Mar 7, 2025 | 144 | Filing |
Mar 7, 2025 | 144 | Filing |
Mar 7, 2025 | 144 | Filing |
Mar 7, 2025 | 144 | Filing |